HALO Halozyme Therapeutics, Inc.

bullish · high conviction track record → $69.57 +0.28 (+0.4%)
Get emailed when HALO changes direction
Mkt Cap $8B P/E 26.2 fwd 6.8 52wk $47.50 - $82.22 Earnings 2026-05-05 44d ago
Insider selling: $59,954,588 sold by 12 insiders (30d)
Est. revisions: +0.1% (1 up, 1 down in 30d)
Factor Model (net -0.1)

Factor Model

net -0.1 1.0 / 10
Est. Revisions
+0.0
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+0.0
Narrative Gap
+0.0

Analysts boost price targets post strong earnings and 2026 guidance

Watch: Monitor Q1 2026 results for evidence that the forward guidance is tracking to plan, especially royalty and partnership revenue contributions. Any miss on ENHANZE or the newer platform contributions (Hypercon, Surf Bio) would challenge the bullish narrative.

Halozyme crushed Q4 results and issued robust 2026 guidance on February 19, sparking a wave of analyst upgrades. Morgan Stanley jumped its price target to $94 from $78, Benchmark lifted to $90 from $75, and Wells Fargo raised to $75 from $65. The company's growth drivers — royalty revenues, ENHANZE partnerships, Hypercon and Surf Bio technology, Vyvgart, and Darzalex — are signaling confidence across the Street.

Three major investment banks raising targets in a single day after earnings suggests strong institutional conviction in the company's near-term trajectory. Morgan Stanley's 21% upside and Benchmark's aggressive Buy positioning indicate the Street sees meaningful runway ahead — this isn't a hold, it's a buy signal.

Evidence

22d ago Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans yahoo-finance
46d ago Is Halozyme Therapeutics (HALO) a Buy Post Earnings? yahoo-finance
49d ago Is Halozyme Therapeutics (HALO) a Buy Post Earnings? yahoo-finance
Fundamentals & Data ▾
Halozyme Therapeutics, Inc. Healthcare · Biotechnology
Mkt Cap
$8B
P/E
26.2 fwd 6.8
Beta
1.03
52w Range
$47.50 - $82.22
Short Interest
13.7M 14.96%
Days to Cover
7.3 -1%
Technicals downtrend
from 52w Hi
0.0%
1w return
+2.2%
Insiders
selling 0B / 8S
EPS Estimate
$1.52 +0.1% 30d 1up / 1dn
Est. Dispersion
11% 5 analysts
Analyst Target
$85 $57 - $96
Options P/C
0.21
Insider Cluster
strong sell 0B / 6S
Fund Convergence
strong Citadel, Renaissance, Bridgewater, Two Sigma, D.E. Shaw
Financials
Revenue
$452M +52% YoY
FCF
$-70M
Gross Margin
83%
Op Margin
53%
Momentum: accelerating
Top Holders
Citadel $80M
Renaissance $38M
Bridgewater $38M
Two Sigma $9M
D.E. Shaw $3M
Recent Filings & Data
insider trade 92
net selling · $59,954,588 sold
12 insiders · 92 transactions (30d)
Recent transactions
TORLEY HELEN I · sell · $634,982
TORLEY HELEN I · exercise · $120,700
TORLEY HELEN I · sell · $2,592,237
TORLEY HELEN I · exercise · $482,800
CAUDILL CORTNEY · sell · $1,955,160
CAUDILL CORTNEY · exercise · $722,006
TORLEY HELEN I · sell · $3,476,157
TORLEY HELEN I · exercise · $603,500
SNYDER MARK HOWARD · other
LABROSSE NICOLE · other
TORLEY HELEN I · other
CAUDILL CORTNEY · other
SNYDER MARK HOWARD · other
LABROSSE NICOLE · other
TORLEY HELEN I · other
TORLEY HELEN I · sell · $3,853,503
CONNAUGHTON BERNADETTE M. · sell · $140,500
SNYDER MARK HOWARD · other
CONNAUGHTON BERNADETTE M. · sell · $59,356
TORLEY HELEN I · sell · $1,141,925
TORLEY HELEN I · exercise · $134,375
TORLEY HELEN I · other
TORLEY HELEN I · sell · $4,167,930
TORLEY HELEN I · exercise · $486,600
CONNAUGHTON BERNADETTE M. · sell · $136,960
CAUDILL CORTNEY · sell · $277,905
CAUDILL CORTNEY · other
TORLEY HELEN I · sell · $4,311,745
CONNAUGHTON BERNADETTE M. · sell · $150,481
LABROSSE NICOLE · sell · $173,584
LABROSSE NICOLE · sell · $1,514,267
LABROSSE NICOLE · exercise · $150,217
TORLEY HELEN I · sell · $4,444,626
CONNAUGHTON BERNADETTE M. · sell · $294,736
TORLEY HELEN I · sell · $3,817,389
TORLEY HELEN I · sell · $3,387,517
TORLEY HELEN I · sell · $3,185,280
SNYDER MARK HOWARD · other
CONNAUGHTON BERNADETTE M. · award
MIYASHITA AKIKO MONI · award
KRISHNAN MAHESH M.D., MPH · award
DUNCAN BARBARA GAYLE · award
HENDERSON JEFFREY WILLIAM · award
POSARD MATTHEW L · award
HENDERSON JEFFREY WILLIAM · sell · $271,467
HENDERSON JEFFREY WILLIAM · sell · $32,217
HENDERSON JEFFREY WILLIAM · sell · $293,458
LABARRE MICHAEL J. · sell · $1,260,681
SNYDER MARK HOWARD · other
LABROSSE NICOLE · other
LABARRE MICHAEL J. · other
TORLEY HELEN I · other
SNYDER MARK HOWARD · other
LABROSSE NICOLE · other
LABARRE MICHAEL J. · other
TORLEY HELEN I · other
HENDERSON JEFFREY WILLIAM · sell · $281,517
HENDERSON JEFFREY WILLIAM · sell · $500,060
MATSUI CONNIE L · other
TORLEY HELEN I · other
LABARRE MICHAEL J. · sell · $1,070,059
LABARRE MICHAEL J. · exercise · $381,255
TORLEY HELEN I · sell · $1,065,743
TORLEY HELEN I · exercise · $277,400
TORLEY HELEN I · sell · $1,706,440
TORLEY HELEN I · exercise · $416,100
LABARRE MICHAEL J. · sell · $1,249,096
LABARRE MICHAEL J. · exercise · $333,000
TORLEY HELEN I · sell · $1,773,790
LABARRE MICHAEL J. · exercise · $102,728
LABARRE MICHAEL J. · sell · $1,228,020
TORLEY HELEN I · sell · $1,714,451
POSARD MATTHEW L · sell · $1,689,294
LABARRE MICHAEL J. · sell · $1,100,023
LABARRE MICHAEL J. · exercise · $232,954
LABROSSE NICOLE · sell · $269,662
LABROSSE NICOLE · exercise · $112,500
LABROSSE NICOLE · sell · $1,557,940
LABROSSE NICOLE · exercise · $675,000
LABARRE MICHAEL J. · sell · $494,260
LABARRE MICHAEL J. · exercise · $81,100
POSARD MATTHEW L · sell · $1,006,300
LABARRE MICHAEL J. · sell · $905,480
LABARRE MICHAEL J. · exercise · $162,200
MATSUI CONNIE L · award
MIYASHITA AKIKO MONI · award
KRISHNAN MAHESH M.D., MPH · award
DUNCAN BARBARA GAYLE · award
HENDERSON JEFFREY WILLIAM · award
POSARD MATTHEW L · award
CONNAUGHTON BERNADETTE M. · award
LABARRE MICHAEL J. · sell · $768,390
3 signals · latest 22d ago

Get alerted when HALO changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →